{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:49:35Z","timestamp":1788569375908,"version":"build-2803163510"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","award":["C\/2020\/1528"],"award-info":[{"award-number":["C\/2020\/1528"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004497","name":"Onderzoeksraad, KU Leuven","doi-asserted-by":"publisher","award":["C14\/21\/111"],"award-info":[{"award-number":["C14\/21\/111"]}],"id":[{"id":"10.13039\/501100004497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["I000321N"],"award-info":[{"award-number":["I000321N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["AKUL15-30\/G0H1216N"],"award-info":[{"award-number":["AKUL15-30\/G0H1216N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00259-024-07025-w","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:57:36Z","timestamp":1733878656000},"page":"1723-1738","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Selective PET imaging of CXCR4 using the Al18F-labeled antagonist LY2510924"],"prefix":"10.1007","volume":"52","author":[{"given":"Muriel Aline","family":"Spahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom Van","family":"Loy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Celen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Koole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe M.","family":"Deroose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Cawthorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Vanduffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Schols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Bormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3692-1608","authenticated-orcid":false,"given":"Frederik","family":"Cleeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"7025_CR1","doi-asserted-by":"publisher","unstructured":"Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4., Semin. Cancer Biol., Jun. 2004;14(3):171\u2013179.https:\/\/doi.org\/10.1016\/j.semcancer.2003.10.003","DOI":"10.1016\/j.semcancer.2003.10.003"},{"key":"7025_CR2","doi-asserted-by":"publisher","unstructured":"Domanska UM et al. A review on CXCR4\/CXCL12 axis in oncology: no place to hide., Eur. J. Cancer Oxf. Engl. 1990, Jan. 2013;49(1):219\u2013230.https:\/\/doi.org\/10.1016\/j.ejca.2012.05.005","DOI":"10.1016\/j.ejca.2012.05.005"},{"key":"7025_CR3","doi-asserted-by":"publisher","unstructured":"Guo F, Wang Y, Liu J, Mok SC, Xue F, Zhang W. CXCL12\/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene. Feb. 2016;35(7):816\u201326. https:\/\/doi.org\/10.1038\/onc.2015.139.","DOI":"10.1038\/onc.2015.139"},{"key":"7025_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","volume":"124","author":"S Chatterjee","year":"2014","unstructured":"Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014;124:31\u201382. https:\/\/doi.org\/10.1016\/B978-0-12-411638-2.00002-1.","journal-title":"Adv Cancer Res"},{"key":"7025_CR5","doi-asserted-by":"publisher","unstructured":"Zhao H, Guo L, Zhao H, Zhao J, Weng H, Zhao B. CXCR4 over-expression and survival in cancer: a system review and meta-analysis., Oncotarget, Mar. 2015;6(7):5022\u20135040.https:\/\/doi.org\/10.18632\/oncotarget.3217","DOI":"10.18632\/oncotarget.3217"},{"key":"7025_CR6","doi-asserted-by":"publisher","unstructured":"Mar\u00e9chal R, et al. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer. May 2009;100(9):1444\u201351. https:\/\/doi.org\/10.1038\/sj.bjc.6605020.","DOI":"10.1038\/sj.bjc.6605020"},{"key":"7025_CR7","doi-asserted-by":"publisher","first-page":"204062072311743","DOI":"10.1177\/20406207231174304","volume":"14","author":"ZD Crees","year":"2023","unstructured":"Crees ZD, Rettig MP, DiPersio JF. Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide. Ther Adv Hematol. 2023;14:20406207231174304. https:\/\/doi.org\/10.1177\/20406207231174304.","journal-title":"Ther Adv Hematol"},{"key":"7025_CR8","doi-asserted-by":"publisher","unstructured":"Sabloff M, Tisseverasinghe S, Babadagli ME, Samant R. Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on? Curr. Oncol. Tor. Ont. Feb. 2021;28(1):903\u2013917.https:\/\/doi.org\/10.3390\/curroncol28010089","DOI":"10.3390\/curroncol28010089"},{"key":"7025_CR9","doi-asserted-by":"publisher","unstructured":"Gourni E et al. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent, J Nucl Med. 2011;52(11):1803\u20132011.https:\/\/doi.org\/10.2967\/jnumed.111.098798","DOI":"10.2967\/jnumed.111.098798"},{"key":"7025_CR10","doi-asserted-by":"publisher","unstructured":"Luo Y, Cao X, Pan Q, Li J, Feng J, Li F. (68)Ga-Pentixafor PET\/CT for Imaging of Chemokine Receptor 4 Expression in Waldenstr\u00f6m Macroglobulinemia\/Lymphoplasmacytic Lymphoma: Comparison to (18)F-FDG PET\/CT., J. Nucl. Med. Off. Publ. Soc. Nucl. Med. Dec. 2019;60(12):1724\u20131729.https:\/\/doi.org\/10.2967\/jnumed.119.226134","DOI":"10.2967\/jnumed.119.226134"},{"key":"7025_CR11","doi-asserted-by":"publisher","unstructured":"Lindenberg L, Ahlman M, Lin F, Mena E, Choyke P. Advances in PET imaging of the CXCR4 receptor: [(68)Ga]Ga-PentixaFor. Semin Nucl Med. Jan. 2024;54(1):163\u201370. https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.09.002.","DOI":"10.1053\/j.semnuclmed.2023.09.002"},{"issue":"1","key":"7025_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7150\/thno.16576","volume":"7","author":"C Lapa","year":"2017","unstructured":"Lapa C, et al. [(68)Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [(18)F]FDG and laboratory values. Theranostics. 2017;7(1):205\u201312. https:\/\/doi.org\/10.7150\/thno.16576.","journal-title":"Theranostics"},{"key":"7025_CR13","doi-asserted-by":"publisher","unstructured":"Chen Z, et al. [(68)Ga]Pentixafor PET\/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [(18)F]FDG PET\/CT. Eur J Nucl Med Mol Imaging. Jun. 2024;51(7):1926\u201336. https:\/\/doi.org\/10.1007\/s00259-024-06621-0.","DOI":"10.1007\/s00259-024-06621-0"},{"key":"7025_CR14","doi-asserted-by":"publisher","unstructured":"Kuyumcu S et al. Prognostic significance of (68)Ga-Pentixafor PET\/CT in multiple myeloma recurrence: a comparison to (18)F-FDG PET\/CT and laboratory results., Ann. Nucl. Med. Oct. 2021;35(10):1147\u20131156.https:\/\/doi.org\/10.1007\/s12149-021-01652-1","DOI":"10.1007\/s12149-021-01652-1"},{"key":"7025_CR15","doi-asserted-by":"publisher","unstructured":"Hu J, et al. Accuracy of Gallium-68 Pentixafor Positron Emission Tomography\u2013Computed Tomography for Subtyping diagnosis of primary Aldosteronism. JAMA Netw Open. Feb. 2023;6(2):e2255609\u20132255609. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.55609.","DOI":"10.1001\/jamanetworkopen.2022.55609"},{"key":"7025_CR16","doi-asserted-by":"publisher","unstructured":"Gao Y, et al. Functional nodules in primary aldosteronism: identification of CXCR4 expression with (68)Ga-pentixafor PET\/CT. Eur Radiol. Feb. 2023;33(2):996\u20131003. https:\/\/doi.org\/10.1007\/s00330-022-09058-x.","DOI":"10.1007\/s00330-022-09058-x"},{"key":"7025_CR17","doi-asserted-by":"publisher","unstructured":"Ding J, Tong A, Hacker M, Feng M, Huo L, Li X. Usefulness of 68 Ga-Pentixafor PET\/CT on Diagnosis and Management of Cushing Syndrome., Clin. Nucl. Med. Aug. 2022;47(8):669\u2013676.https:\/\/doi.org\/10.1097\/RLU.0000000000004244","DOI":"10.1097\/RLU.0000000000004244"},{"key":"7025_CR18","doi-asserted-by":"publisher","unstructured":"Wang M, Zhang J, Ma J, Liu L, Wang J, Zhang C. Imaging findings and clinical relevance of 68Ga-Pentixafor PET in atherosclerosis: a systematic review. BMC Med Imaging. Oct. 2023;23(1):166. https:\/\/doi.org\/10.1186\/s12880-023-01134-y.","DOI":"10.1186\/s12880-023-01134-y"},{"key":"7025_CR19","doi-asserted-by":"publisher","unstructured":"Li X et al. [(68)Ga]Pentixafor PET\/MR imaging of chemokine receptor 4 expression in the human carotid artery., Eur. J. Nucl. Med. Mol. Imaging. Jul. 2019;46(8):1616\u20131625.https:\/\/doi.org\/10.1007\/s00259-019-04322-7","DOI":"10.1007\/s00259-019-04322-7"},{"issue":"3","key":"7025_CR20","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.chest.2020.08.2043","volume":"159","author":"T Derlin","year":"2021","unstructured":"Derlin T, et al. Clinical Molecular Imaging of Pulmonary CXCR4 expression to Predict Outcome of Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis. Chest. 2021;159(3):1094\u2013106. https:\/\/doi.org\/10.1016\/j.chest.2020.08.2043.","journal-title":"Chest"},{"key":"7025_CR21","doi-asserted-by":"publisher","unstructured":"Derlin T et al. Imaging of chemokine receptor CXCR4 expression in culprit and nonculprit coronary atherosclerotic plaque using motion-corrected [(68)Ga]pentixafor PET\/CT., Eur. J. Nucl. Med. Mol. Imaging. Oct. 2018;45(11):1934\u20131944.https:\/\/doi.org\/10.1007\/s00259-018-4076-2","DOI":"10.1007\/s00259-018-4076-2"},{"issue":"5","key":"7025_CR22","first-page":"311","volume":"8","author":"E Pauwels","year":"2018","unstructured":"Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin receptor PET ligands - the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018;8(5):311\u201331.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"7025_CR23","doi-asserted-by":"publisher","unstructured":"Sanchez-Crespo A. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot Data Instrum Methods Use Agric Ind Med. Jun. 2013;76:55\u201362. https:\/\/doi.org\/10.1016\/j.apradiso.2012.06.034.","DOI":"10.1016\/j.apradiso.2012.06.034"},{"key":"7025_CR24","doi-asserted-by":"publisher","unstructured":"Hannes, Leupe, et al. 18F-Labeled somatostatin analogs as PET Tracers for the somatostatin receptor: ready for clinical use. J Nucl Med. May 2023;265622. https:\/\/doi.org\/10.2967\/jnumed.123.265622.","DOI":"10.2967\/jnumed.123.265622"},{"key":"7025_CR25","unstructured":"Jensen M, Clark JC. Direct production of Ga-68 from proton bombardment of concentrated aqueous solutions of [Zn-68] Zinc Chloride, 2011. [Online]. Available: https:\/\/api.semanticscholar.org\/CorpusID:100008717"},{"key":"7025_CR26","doi-asserted-by":"publisher","unstructured":"Poschenrieder A, et al. First (18)F-Labeled Pentixafor-based Imaging Agent for PET Imaging of CXCR4 expression in vivo. Tomogr Ann Arbor Mich. Jun. 2016;2(2):85\u201393. https:\/\/doi.org\/10.18383\/j.tom.2016.00130.","DOI":"10.18383\/j.tom.2016.00130"},{"key":"7025_CR27","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1158\/1078-0432.CCR-13-2686","volume":"20","author":"MD Galsky","year":"2014","unstructured":"Galsky MD, et al. A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer. Clin Cancer Res. 2014;20:3581\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2686.","journal-title":"Clin Cancer Res"},{"key":"7025_CR28","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/1535-7163.MCT-14-0850","volume":"14","author":"SB Peng","year":"2015","unstructured":"Peng SB, et al. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Mol Cancer Ther. 2015;14:480\u201390. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0850. no. 2.","journal-title":"Mol Cancer Ther"},{"key":"7025_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.lungcan.2016.12.020","volume":"105","author":"R Salgia","year":"2017","unstructured":"Salgia R, et al. A randomized phase II study of LY2510924 and carboplatin\/etoposide versus carboplatin\/etoposide in extensive-disease small cell lung cancer. Lung Cancer. 2017;105:7\u201313. https:\/\/doi.org\/10.1016\/j.lungcan.2016.12.020.","journal-title":"Lung Cancer"},{"issue":"1","key":"7025_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/pancan.2019.0018","volume":"6","author":"MH O\u2019Hara","year":"2020","unstructured":"O\u2019Hara MH, et al. Safety and Pharmacokinetics of CXCR4 peptide antagonist, LY2510924, in combination with Durvalumab in Advanced Refractory Solid tumors. J Pancreat Cancer. 2020;6(1):21\u201331. https:\/\/doi.org\/10.1089\/pancan.2019.0018.","journal-title":"J Pancreat Cancer"},{"key":"7025_CR31","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fonc.2018.00369","volume":"8","author":"P Boddu","year":"2018","unstructured":"Boddu P, et al. Initial report of a phase I study of LY2510924, Idarubicin, and Cytarabine in Relapsed\/Refractory Acute myeloid leukemia. Front Oncol. 2018;8:369. https:\/\/doi.org\/10.3389\/fonc.2018.00369.","journal-title":"Front Oncol"},{"key":"7025_CR32","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11523-016-0434-9","volume":"11","author":"JD Hainsworth","year":"2016","unstructured":"Hainsworth JD, et al. Open-label phase 2 study of the CXCR4 inhibitor LY2510924 in combination with Sunitinib Versus Sunitinib alone in patients with metastatic renal cell carcinoma (RCC). Target Oncol. 2016;11:643\u201353. https:\/\/doi.org\/10.1007\/s11523-016-0434-9. no. 5A Randomized.","journal-title":"Target Oncol"},{"key":"7025_CR33","doi-asserted-by":"publisher","unstructured":"Peng T et al. Preclinical Evaluation of [64 Cu]NOTA-CP01 as a PET Imaging Agent for Metastatic Esophageal Squamous Cell Carcinoma, Mol Pharm. 2021;18(9):3638\u20133648.https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00600","DOI":"10.1021\/acs.molpharmaceut.1c00600"},{"key":"7025_CR34","doi-asserted-by":"publisher","first-page":"15284","DOI":"10.1038\/s41598-019-51754-0","volume":"9","author":"K Suzuki","year":"2019","unstructured":"Suzuki K, Ui T, Nagano A, Hino A, Arano Y. C-terminal-modified LY2510924: a versatile scaffold for targeting C-X-C chemokine receptor type 4. Sci Rep. 2019;9:15284. https:\/\/doi.org\/10.1038\/s41598-019-51754-0. no. 1.","journal-title":"Sci Rep"},{"key":"7025_CR35","doi-asserted-by":"publisher","unstructured":"Lau J et al. [(68)Ga]Ga\/[(177)Lu]Lu-BL01, a Novel Theranostic Pair for Targeting C-X-C Chemokine Receptor 4., Mol. Pharm. Nov. 2019;16(11):4688\u20134695.https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00808","DOI":"10.1021\/acs.molpharmaceut.9b00808"},{"key":"7025_CR36","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-21-3284","volume":"28","author":"D Kwon","year":"2022","unstructured":"Kwon D, et al. Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy using C-X-C chemokine receptor type 4 Radioligands. Clin Cancer Res. 2022;28:1628\u201339. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3284. no. 8.","journal-title":"Clin Cancer Res"},{"key":"7025_CR37","doi-asserted-by":"publisher","unstructured":"Kwon D, et al. High-contrast CXCR4-Targeted (18)F-PET imaging using a potent and selective antagonist. Mol Pharm. Jan. 2021;18(1):187\u201397. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00785.","DOI":"10.1021\/acs.molpharmaceut.0c00785"},{"key":"7025_CR38","doi-asserted-by":"publisher","unstructured":"Tshibangu T, et al. Automated GMP compliant production of [(18)F]AlF-NOTA-octreotide. EJNMMI Radiopharm Chem. Jan. 2020;5(1). https:\/\/doi.org\/10.1186\/s41181-019-0084-1.","DOI":"10.1186\/s41181-019-0084-1"},{"key":"7025_CR39","doi-asserted-by":"publisher","unstructured":"Spahn MA et al. Second generation Al(18)F-labeled D-amino acid peptide for CXCR4 targeted molecular imaging. Nucl Med Biol. Mar. 2024;132\u2013133:P. 108906.https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108906","DOI":"10.1016\/j.nucmedbio.2024.108906"},{"key":"7025_CR40","doi-asserted-by":"publisher","unstructured":"Ghai A et al. Development of [(89)Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma. Eur J. Nucl Med Mol Imaging.May. 2021;48(5):1302\u20131311.https:\/\/doi.org\/10.1007\/s00259-020-05097-y","DOI":"10.1007\/s00259-020-05097-y"},{"key":"7025_CR41","doi-asserted-by":"publisher","unstructured":"Lam C, et al. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica. Jul. 2018;103(7):1218\u201328. https:\/\/doi.org\/10.3324\/haematol.2017.174482.","DOI":"10.3324\/haematol.2017.174482"},{"key":"7025_CR42","doi-asserted-by":"publisher","unstructured":"Luyten K, et al. D-Peptide-based probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy. Pharmaceutics. 2021;13(10). https:\/\/doi.org\/10.3390\/pharmaceutics13101619.","DOI":"10.3390\/pharmaceutics13101619"},{"key":"7025_CR43","doi-asserted-by":"publisher","unstructured":"Peng S-B et al. Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587. Oncotarget. Nov. 2017;55(8):94619\u201394634.https:\/\/doi.org\/10.18632\/oncotarget.21816","DOI":"10.18632\/oncotarget.21816"},{"key":"7025_CR44","doi-asserted-by":"publisher","unstructured":"Coudert E, et al. Annotation of biologically relevant ligands in UniProtKB using ChEBI. Bioinformatics. 2023;39(1). https:\/\/doi.org\/10.1093\/bioinformatics\/btac793.","DOI":"10.1093\/bioinformatics\/btac793"},{"key":"7025_CR45","doi-asserted-by":"publisher","first-page":"20565","DOI":"10.1073\/pnas.1012865107","volume":"107","author":"S J\u00e4hnichen","year":"2010","unstructured":"J\u00e4hnichen S, et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci U S A. 2010;107:20565\u201370. https:\/\/doi.org\/10.1073\/pnas.1012865107.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7025_CR46","doi-asserted-by":"publisher","unstructured":"Pauwels E et al. [(18)F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [(68)Ga]Ga-DOTATATE in neuroendocrine tumour patients Eur J Nucl Med Mol Imaging. Dec. 2020;47(13):3033\u20133046.https:\/\/doi.org\/10.1007\/s00259-020-04918-4","DOI":"10.1007\/s00259-020-04918-4"},{"key":"7025_CR47","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264563","author":"E Pauwels","year":"2022","unstructured":"Pauwels E, et al. 18 F-AlF-NOTA-octreotide outperforms 68 Ga-DOTA-TATE\/-NOC PET in neuroendocrine tumor patients: results from a prospective, multicenter study. J Nucl Med. 2022. https:\/\/doi.org\/10.2967\/jnumed.122.264563.","journal-title":"J Nucl Med"},{"key":"7025_CR48","doi-asserted-by":"publisher","unstructured":"Hrycay EG, Bandiera SM. Expression, function and regulation of mouse cytochrome P450 enzymes: comparison with human P450 enzymes Curr Drug Metab. Dec. 2009;10(10):1151\u20131183.https:\/\/doi.org\/10.2174\/138920009790820138","DOI":"10.2174\/138920009790820138"},{"key":"7025_CR49","doi-asserted-by":"publisher","unstructured":"Kharasch ED, Thummel KE. Identification of Cytochrome P450 2E1 as the Predominant Enzyme Catalyzing Human Liver Microsomal Defluorination of Sevoflurane Isoflurane and Methoxyflurane Anesthesiology. Oct. 1993;79(4):795\u2013807.https:\/\/doi.org\/10.1097\/00000542-199310000-00023","DOI":"10.1097\/00000542-199310000-00023"},{"key":"7025_CR50","doi-asserted-by":"publisher","unstructured":"Lian J, Nelson R, Lehner R. Carboxylesterases in lipid metabolism: from mouse to human. Protein Cell. Feb. 2018;9(2):178\u201395. https:\/\/doi.org\/10.1007\/s13238-017-0437-z.","DOI":"10.1007\/s13238-017-0437-z"},{"key":"7025_CR51","doi-asserted-by":"publisher","unstructured":"Rafii S et al. Platelet-derived SDF-1 primes the pulmonary capillary vascular niche to drive lung alveolar regeneration, Nat Cell Biol. Feb. 2015;17(2):123\u2013136.https:\/\/doi.org\/10.1038\/ncb3096","DOI":"10.1038\/ncb3096"},{"key":"7025_CR52","doi-asserted-by":"publisher","unstructured":"Gilbert W, et al. Stromal cell-derived factor-1 (CXCL12) and its role in bone and muscle biology. Cytokine. Nov. 2019;123:154783. https:\/\/doi.org\/10.1016\/j.cyto.2019.154783.","DOI":"10.1016\/j.cyto.2019.154783"},{"key":"7025_CR53","doi-asserted-by":"publisher","unstructured":"Jurczyszyn A et al. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice Am J Hematol. Jun. 2016;91(6):575\u2013580.https:\/\/doi.org\/10.1002\/ajh.24351","DOI":"10.1002\/ajh.24351"},{"key":"7025_CR54","doi-asserted-by":"publisher","unstructured":"Cavanna L, Invernizzi R, Berte\u2019 R, Vallisa D, Buscarini L. Meningeal involvement in multiple myeloma: report of a case with cytologic and immunocytochemical diagnosis Acta Cytol. Jun. 1996;40(3):571\u2013575.https:\/\/doi.org\/10.1159\/000333918","DOI":"10.1159\/000333918"},{"key":"7025_CR55","doi-asserted-by":"publisher","unstructured":"Kundu S et al. Multiple Myeloma and Renal Failure: Mechanisms Diagnosis and Management Cureus. Feb. 2022;14(2) P. e22585.https:\/\/doi.org\/10.7759\/cureus.22585","DOI":"10.7759\/cureus.22585"},{"key":"7025_CR56","doi-asserted-by":"publisher","unstructured":"Leung N, Rajkumar SV. Multiple myeloma with acute light chain cast nephropathy. Blood Cancer J. Mar. 2023;13(1):46. https:\/\/doi.org\/10.1038\/s41408-023-00806-w.","DOI":"10.1038\/s41408-023-00806-w"},{"issue":"2","key":"7025_CR57","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14797\/mdcvj.1070","volume":"18","author":"KR Baker","year":"2022","unstructured":"Baker KR. Light chain amyloidosis: epidemiology, staging, and prognostication. Methodist DeBakey Cardiovasc J. 2022;18(2):27\u201335. https:\/\/doi.org\/10.14797\/mdcvj.1070.","journal-title":"Methodist DeBakey Cardiovasc J"},{"key":"7025_CR58","doi-asserted-by":"publisher","unstructured":"Serfling SE et al. Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [(68)Ga]Ga-PentixaFor PET\/CT Mol Imaging Biol. Aug. 2022;24(4):659\u2013665.https:\/\/doi.org\/10.1007\/s11307-022-01717-1","DOI":"10.1007\/s11307-022-01717-1"},{"key":"7025_CR59","doi-asserted-by":"publisher","first-page":"618","DOI":"10.7150\/thno.11251","volume":"5","author":"HJ Wester","year":"2015","unstructured":"Wester HJ, et al. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics. 2015;5:618\u201330. https:\/\/doi.org\/10.7150\/thno.11251.","journal-title":"Theranostics"},{"key":"7025_CR60","doi-asserted-by":"publisher","unstructured":"Heinze B et al. Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma Hypertens Dallas Tex 1979. Feb. 2018;71(2):317\u2013325.https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.09975","DOI":"10.1161\/HYPERTENSIONAHA.117.09975"},{"key":"7025_CR61","doi-asserted-by":"publisher","unstructured":"Chigoho DM, Bridoux J, Hernot S. Reducing the renal retention of low- to moderate-molecular-weight radiopharmaceuticals. Curr Opin Chem Biol. Aug. 2021;63:219\u201328. https:\/\/doi.org\/10.1016\/j.cbpa.2021.06.008.","DOI":"10.1016\/j.cbpa.2021.06.008"},{"issue":"13","key":"7025_CR62","doi-asserted-by":"publisher","first-page":"5971","DOI":"10.7150\/thno.75336","volume":"12","author":"S Ahenkorah","year":"2022","unstructured":"Ahenkorah S, et al. 3p-C-NETA: a versatile and effective chelator for development of Al(18)F-labeled and therapeutic radiopharmaceuticals. Theranostics. 2022;12(13):5971\u201385. https:\/\/doi.org\/10.7150\/thno.75336.","journal-title":"Theranostics"},{"key":"7025_CR63","doi-asserted-by":"publisher","unstructured":"Bj\u00f6rndal A, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol. Oct. 1997;71(10):7478\u201387. https:\/\/doi.org\/10.1128\/JVI.71.10.7478-7487.1997.","DOI":"10.1128\/JVI.71.10.7478-7487.1997"},{"key":"7025_CR64","doi-asserted-by":"publisher","unstructured":"Schols D, Est\u00e9 JA, Cabrera C, De Clercq E. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J Virol. May 1998;72(5):4032\u20137. https:\/\/doi.org\/10.1128\/JVI.72.5.4032-4037.1998.","DOI":"10.1128\/JVI.72.5.4032-4037.1998"},{"key":"7025_CR65","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1742-4690-1-2","volume":"1","author":"K Princen","year":"2004","unstructured":"Princen K, Hatse S, Vermeire K, De Clercq E, Schols D. Establishment of a novel CCR5 and CXCR4 expressing CD4\u2009+\u2009cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists. Retrovirology. 2004;1:2. https:\/\/doi.org\/10.1186\/1742-4690-1-2.","journal-title":"Retrovirology"},{"key":"7025_CR66","doi-asserted-by":"publisher","first-page":"e00557","DOI":"10.1016\/j.heliyon.2018.e00557","volume":"4","author":"T D\u2019huys","year":"2018","unstructured":"D\u2019huys T, Claes S, Van Loy T, Schols D. CXCR7\/ACKR3-targeting ligands interfere with X7 HIV-1 and HIV-2 entry and replication in human host cells. Heliyon. 2018;4:e00557. https:\/\/doi.org\/10.1016\/j.heliyon.2018.e00557. no. 3.","journal-title":"Heliyon"},{"key":"7025_CR67","doi-asserted-by":"publisher","unstructured":"Schoofs G, Van Hout A, D\u2019huys T, Schols D, Van Loy T. A Flow Cytometry-based assay to identify compounds that disrupt binding of fluorescently-labeled CXC Chemokine Ligand 12 to CXC chemokine receptor 4. J Vis Exp. 2018;133. https:\/\/doi.org\/10.3791\/57271.","DOI":"10.3791\/57271"},{"key":"7025_CR68","doi-asserted-by":"publisher","unstructured":"Percie du N, Sert, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. Jul. 2020;18(7):e3000410. https:\/\/doi.org\/10.1371\/journal.pbio.3000410.","DOI":"10.1371\/journal.pbio.3000410"},{"key":"7025_CR69","doi-asserted-by":"publisher","unstructured":"Benjamin P, Burke, et al. 64Cu PET imaging of the CXCR4 chemokine receptor using a cross-bridged cyclam bis-tetraazamacrocyclic antagonist. J Nucl Med. Jan. 2020;61(1):123. https:\/\/doi.org\/10.2967\/jnumed.118.218008.","DOI":"10.2967\/jnumed.118.218008"},{"issue":"12","key":"7025_CR70","doi-asserted-by":"publisher","first-page":"e51892","DOI":"10.1371\/journal.pone.0051892","volume":"7","author":"PO Hofgaard","year":"2012","unstructured":"Hofgaard PO, et al. A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PLoS ONE. 2012;7(12):e51892. https:\/\/doi.org\/10.1371\/journal.pone.0051892.","journal-title":"PLoS ONE"},{"key":"7025_CR71","doi-asserted-by":"publisher","unstructured":"Ribeiro FM, Correia PMM, Santos AC, Veloso JFCA. A guideline proposal for mice preparation and care in (18)F-FDG PET imaging EJNMMI Res. Aug. 2022;12(1) P. 49.https:\/\/doi.org\/10.1186\/s13550-022-00921-y","DOI":"10.1186\/s13550-022-00921-y"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-07025-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-07025-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-07025-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T19:49:06Z","timestamp":1742672946000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-07025-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["7025"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-07025-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"assertion":[{"value":"29 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All of the herein discussed animal studies were conducted according to the international, national, and institutional regulations governing the care and use of animals. Each experiment was approved by the KU Leuven ethical review board (Reference P010\/2023 (mice studies) and P112\/2019 (non-human primate study)). This research did not involve any human material or human participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All the authors approved the publication of the article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}